Allergan oral migraine drug succeeds in study

Allergan oral migraine drug succeeds in study(Reuters) – Allergan Plc said on Monday its oral migraine drug met the main goal across all doses in a study, with a statistically significant reduction in monthly headache days in patients with episodic migraine. The treatment, atogepant, belongs to a class of migraine drugs also being developed by Eli Lilly and Alder Biopharmaceuticals that target a protein associated with pain signaling called calcitonin gene-related peptide (CGRP). Last month, the U.S. Food and Drug Administration approved Amgen Inc’s CGRP treatment Aimovig, which is self injected monthly and will have a list price of $6,900 a year, or $575 a month.


Source: Yahoo! News

Migraine drug delay would compound Teva's troubles

Migraine drug delay would compound Teva's troublesBy Steven Scheer and Tova Cohen TEL AVIV (Reuters) – Teva Pharmaceutical Industries is counting on its new migraine treatment to haul it out of the doldrums. U.S. regulatory concerns about the manufacturing process could push approval of fremanezumab back to 2019. This is likely to put the Israeli drugmaker behind two of its rivals – Amgen and Eli Lilly – in the race to market for a migraine treatment, according to industry experts.


Source: Yahoo! News